Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

0.6125 -0.0275 (-4.30%)
Delayed Quote Updated: 2:28 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lantern Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Powering the AI Economy: New to The Street Show #776 Premieres Tonight on Bloomberg Television
The Show Broadcasts Across the U.S., Latin America, Southeast Asia and MENA as Sponsored Programming 
From New to The Street
Via ACCESS Newswire
News headline image
New to The Street Show 775 Premieres Tonight on Bloomberg Television Across the United States, Latin America, MENA and Southeast Asia, Featuring American Fusion, HPB, T-REX Acquisition Corp. and SyncMeOn
Fusion energy, solid-state batteries, digital-asset infrastructure and AI-era restaurant procurement lead a four-region broadcast, with commercials from BioVie, Lantern Pharma, Big Sky Industrial and... 
From New to The Street
Via ACCESS Newswire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 15
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives Taiwan Approvals to Advance Phase 2 HARMONIC(TM) Trial
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
From Lantern Pharma Inc.
Via Business Wire
NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Announces $4 Million Registered Direct Offering
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
Gold-backed payments, enterprise AI, a Long COVID clinical readout and AI-powered school safety lead a 6:30 p.m. ET broadcast reaching audiences across the United States, Latin America and MENA 
From New to The Street
Via ACCESS Newswire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present Open-Medicine AI Growth Plan, Live Platform Demo in Webinar
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
From Lantern Pharma Inc.
Via Business Wire
MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
BioVie (Nasdaq:BIVI) CEO Cuong Do Discusses the Company's Recent Long COVID Clinical Results and the Potential of Bezisterim to Address Significant Unmet Patient Needs 
From New to The Street
Via ACCESS Newswire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Show 771 Airs Today on Bloomberg, Featuring Bill Mobley, Panna Sharma, Phillip Toppino and Dr. Kelley Gurley
The program broadcasts at 6:30 p.m. ET across the United States, Latin America, MENA and Southeast Asia-supported by New to The Street's 6.3 million-plus YouTube subscriber ecosystem, second only to... 
From New to The Street
Via ACCESS Newswire
News headline image
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)
October 3 Southeast Asia launch will add distribution reaching approximately 68 million households 
From New to The Street
Via ACCESS Newswire
News headline image
New to The Street Broadcasting Today at 6:30 PM EST on Bloomberg Television Across the U.S., Latin America and MENA-Featuring FreeCast (NASDAQ: CAST), Metaterra Holdings (MTHI) and SafeSpace Global (SGCC)
From New to The Street
Via ACCESS Newswire
NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline, Establishes Open Medicine AI
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results
From New to The Street
Via ACCESS Newswire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules Second-Quarter 2026 Results Webcast
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street TV Announces Broadcast of Show No. 765 Tonight on Bloomberg Television at 6:30 PM ET Featuring Envoy Medical, Graphene Manufacturing Group, Rhino Bitcoin, and Big Sky Industrial
From New to The Street
Via ACCESS Newswire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) EMA Clears LP-184 Bladder Cancer Trial in Europe
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
From Lantern Pharma Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.